Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Vaccinex Price Performance
Shares of Vaccinex stock remained flat at $1.03 during trading on Monday. The company had a trading volume of 45,135 shares, compared to its average volume of 596,004. Vaccinex has a twelve month low of $0.90 and a twelve month high of $2.60. The company has a quick ratio of 10.00, a current ratio of 10.00 and a debt-to-equity ratio of 0.01. The stock has a market cap of $43.94 million, a price-to-earnings ratio of -2.00 and a beta of 0.99. The business's fifty day simple moving average is $1.13 and its 200-day simple moving average is $1.25.
Vaccinex (NASDAQ:VCNX - Get Rating) last released its earnings results on Monday, May 16th. The company reported ($0.12) earnings per share (EPS) for the quarter.